Mercury Laboratories Falls 5.06% Amid Profit Decline and Valuation Pressure
2026-11-08 11:00:10Key Events This Week Nov 2: Stock opens sharply lower at Rs.760.05 (-3.79%) despite Sensex rally Nov 5: Q2 FY2027 results reveal profit plunge; stock rebounds +4.99% Nov 6: Downgrade to Strong Sell and valuation shift to expensive weigh on shares Nov 6: Week closes at Rs.750.00 (-6.02% on day), underperforming Sensex Week OpenRs.790.00 <div class=...
Read More
Mercury Laboratories Ltd is Rated Strong Sell
2026-11-01 10:10:46Mercury Laboratories Ltd is rated 'Strong Sell' by MarketsMOJO, a rating that was last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 November 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.
Read More
Mercury Laboratories Ltd is Rated Strong Sell
2026-10-21 10:10:56Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.
Read More
Mercury Laboratories Ltd is Rated Strong Sell
2026-10-10 10:10:49Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Mercury Laboratories Ltd Downgraded to Strong Sell Amidst Weak Financials and Bearish Technicals
2026-09-16 08:38:50Mercury Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 15 Sep 2026, reflecting deteriorating technical indicators and disappointing financial performance. Despite some valuation appeal, the company’s weak operating trends and bearish technical signals have prompted a reassessment of its investment prospects within the Pharmaceuticals & Biotechnology sector.
Read More
Mercury Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges
2026-09-11 08:09:40Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 10 September 2026, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The company’s Mojo Score now stands at 34.0, reflecting a cautious but slightly more optimistic stance amid mixed signals from valuation, quality, financial trends, and technical analysis.
Read More
Mercury Laboratories Ltd is Rated Strong Sell
2026-09-03 10:11:24Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read MoreUpdates On New Small Volume Parenteral (Svps) Plant At Jarod
19-Nov-2026 | Source : BSEUpdate on Small volume Parenteral Plant is attached
Announcement under Regulation 30 (LODR)-Change in Management
14-Nov-2026 | Source : BSEIntimation about the appointment of Factory manger-HR
Announcement under Regulation 30 (LODR)-Newspaper Publication
07-Nov-2026 | Source : BSESubmission of Newspaper advertisement published regarding postal ballot notice
Corporate Actions
No Upcoming Board Meetings
Mercury Laboratories Ltd has declared 35% dividend, ex-date: 21 Sep 26
No Splits history available
No Bonus history available
No Rights history available